Evidence map›Paper›PMID 31560388›Full record

ArticleJAMA network open2019

Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.

Gordon P Watt, Anne S Reiner, Susan A Smith, Daniel O Stram, Marinela Capanu, Kathleen E Malone, Charles F Lynch, Esther M John, Julia A Knight, Lene Mellemkjær and 16 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Cancer Effects of Low to Moderate Doses of Ionizing Radiation in Young People with Cancer-Predisposing Conditions: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 16 institutions in 4 countries.

Gordon P WattMemorial Sloan Kettering Cancer Center, New York, New York.
Anne S ReinerMemorial Sloan Kettering Cancer Center, New York, New York.
Susan A SmithDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston.
Daniel O StramDepartment of Preventive Medicine, University of Southern California, Los Angeles.
Marinela CapanuMemorial Sloan Kettering Cancer Center, New York, New York.
Kathleen E MaloneFred Hutchinson Cancer Research Center, Seattle, Washington.
Charles F LynchDepartment of Epidemiology, University of Iowa, Iowa City.
Esther M JohnStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Julia A KnightLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
Lene MellemkjærDanish Cancer Society Research Center, Copenhagen, Denmark.
Leslie BernsteinBeckman Research Institute, City of Hope National Medical Center, Duarte, California.
Jennifer D BrooksEpidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Meghan WoodsMemorial Sloan Kettering Cancer Center, New York, New York.
Xiaolin LiangMemorial Sloan Kettering Cancer Center, New York, New York.
Robert W HaileCedars-Sinai Medical Center, Los Angeles, California.
Nadeem RiazMemorial Sloan Kettering Cancer Center, New York, New York.
David V ContiDepartment of Preventive Medicine, University of Southern California, Los Angeles.
Mark RobsonMemorial Sloan Kettering Cancer Center, New York, New York.
David DugganTranslational Genomics Research Institute, An Affiliate of City of Hope, Phoenix, Arizona.
John D BoiceNational Council on Radiation Protection and Measurements, Bethesda, Maryland.
Roy E ShoreNew York University School of Medicine, New York.
Marc TischkowitzUniversity of Cambridge, Cambridge, England.
Irene OrlowMemorial Sloan Kettering Cancer Center, New York, New York.
Duncan C ThomasDepartment of Preventive Medicine, University of Southern California, Los Angeles.
Patrick ConcannonGenetics Institute, University of Florida, Gainesville.
Jonine L BernsteinMemorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USUniversity of Southern California · USCedars-Sinai Medical Center · USCity of Hope · USCity Of Hope National Medical Center · USDanish Cancer Society · DKFred Hutch Cancer Center · USLunenfeld-Tanenbaum Research Institute · CANational Council on Radiation Protection and Measurements · USNew York University · USPublic Health Ontario · CAStanford University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Cambridge · GBUniversity of Florida · USUniversity of Iowa · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Statistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul Marjoram · 2016 to 2026
$25.5M
Novel DNA damage response gene from genomic screeningR01ES027121 · NIEHS · UNIVERSITY OF FLORIDA · PI CONCANNON, PATRICK · 2016 to 2020
$1.6M
NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA008748NIEHS NIH HHS R01 ES027121
6 · The paper itself

Abstract

Importance: Radiation therapy for breast cancer is associated with increased risk of a second primary contralateral breast cancer, but the genetic factors modifying this association are not well understood. Objective: To determine whether a genetic risk score comprising single nucleotide polymorphisms in the nonhomologous end-joining DNA repair pathway is associated with radiation-associated contralateral breast cancer. Design, Setting, and Participants: This case-control study included a case group of women with contralateral breast cancer that was diagnosed at least 1 year after a first primary breast cancer who were individually matched to a control group of women with unilateral breast cancer. Inclusion criteria were receiving a first invasive breast cancer diagnosis prior to age 55 years between 1985 and 2008. Women were recruited through 8 population-based cancer registries in the United States, Canada, and Denmark as part of the Women's Environment, Cancer, and Radiation Epidemiology Studies I (November 2000 to August 2004) and II (March 2010 to December 2012). Data analysis was conducted from July 2017 to August 2019. Exposures: Stray radiation dose to the contralateral breast during radiation therapy for the first breast cancer. A novel genetic risk score comprised of genetic variants in the nonhomologous end-joining DNA repair pathway was considered the potential effect modifier, dichotomized as high risk if the score was above the median of 74 and low risk if the score was at or below the median. Main Outcomes and Measures: The main outcome was risk of contralateral breast cancer associated with stray radiation dose stratified by genetic risk score, age, and latency. Results: A total of 5953 women were approached for study participation, and 3732 women (62.7%) agreed to participate. The median (range) age at first diagnosis was 46 (23-54) years. After 5 years of latency or more, among women who received the first diagnosis when they were younger than 40 years, exposure to 1.0 Gy (to convert to rad, multiply by 100) or more of stray radiation was associated with a 2-fold increased risk of contralateral breast cancer compared with women who were not exposed (rate ratio, 2.0 [95% CI, 1.1-3.6]). The risk was higher among women with a genetic risk score above the median (rate ratio, 3.0 [95% CI, 1.1-8.1]), and there was no association among women with a genetic risk score below the median (rate ratio, 1.3 [95% CI, 0.5-3.7]). Among younger women with a high genetic risk score, the attributable increased risk for contralateral breast cancer associated with stray radiation dose was 28%. Conclusions and Relevance: This study found an increased risk of contralateral breast cancer that was attributable to stray radiation exposure among women with a high genetic risk score and who received a first breast cancer diagnosis when they were younger than 40 years after 5 years or more of latency. This genetic risk score may help guide treatment and surveillance for women with breast cancer.

Indexed as

AdultBreast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMiddle AgedNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPolymorphism, Single NucleotideRadiotherapyRisk AssessmentRisk Factors

Identifiers

PMID31560388
PMCPMC6777239
OpenAlexW2977218692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.